Question follow-through · 107760

Prostate Cancer: Screening

To ask the Secretary of State for Health and Social Care, what steps he is planning to take to ensure that the final Equality Impact Assessment for the prostate cancer screening recommendation does not (a) continue and (b) worsen existing health inequalit

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
22 Jan 2026
Target answer date
29 Jan 2026
Answer
2 Feb 2026 · 11 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 22 Jan 2026

    Question tabled

    To ask the Secretary of State for Health and Social Care, what steps he is planning to take to ensure that the final Equality Impact Assessment for the prostate cancer screening recommendation does not (a) continue and (b) worsen existing health inequalit

  2. 29 Jan 2026

    Target answer date

    Date supplied by the official written-questions record.

  3. 2 Feb 2026

    Answer published

    On 28 November, the UK National Screening Committee opened a 12-week public consultation on a draft recommendation on screening for prostate cancer. We anticipate a final recommendation in early 2026. After which, my Rt Hon. Friend, the Secretary of State...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

No later same-department questions indexed.

This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.